PolyNovo Receives CE Mark Approval for NovoPore
Filed with ASX · · 2 pages · English
Watch PolyNovo's latest callPolyNovo (ASX:PNV) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of PolyNovo (ASX:PNV) Q4 2026 Earnings Call6ix is checking which company filed this.
Story so far
Earlier from PolyNovo
- Financial Result Guidance
- VAC Human Clinical Trial Update
- US FDA approval
- US BARDA Contract Application and BTM Trial Update
- Update on US Partner Collaboration
Later from PolyNovo
- AOD9604 Positive in Osteoarthritis Animal Model
- Positive Results from NovoSorb Human Clinical Trial
- Topical Negative Pressure Human Trial Completed
- Trading halt and request
- First PolyNovo Patent Allowed in US
Follow PolyNovo into a list and get an email when it puts out news.
Follow PolyNovo